Welcome to our dedicated page for BIOCORRX NEW news (Ticker: BICX), a resource for investors and traders seeking the latest updates and insights on BIOCORRX NEW stock.
BioCorRx Inc. (BICX) is a leading healthcare solutions company focused on transforming the lives of individuals grappling with alcohol and opioid addiction. Utilizing a proprietary recovery program, the company offers a long-lasting FDA-approved naltrexone implant that significantly reduces cravings. With a network of treatment centers across the United States, BioCorRx's program is comprehensive, affordable, and highly effective, fostering an improved quality of life for individuals in recovery.
Rhea-AI Summary
BioCorRx Inc. (OTCQB: BICX), a developer of innovative substance abuse treatment programs, provided a business update for Q2 2024. Key highlights include:
1. Expansion of intellectual property portfolio with a new international patent from Israel for weight loss treatment using naltrexone implants.
2. A new USPTO patent for a novel compound potentially reducing opioid withdrawal symptoms.
3. A $11 million grant from NIDA for developing BICX104, a long-duration naltrexone implant for methamphetamine use disorder (MUD).
The company remains focused on addressing global unmet medical needs in obesity and substance abuse, with ongoing progress in development efforts and strategic priorities aimed at creating shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
BioCorRx Inc. (BICX) announces the granting of a new patent by the USPTO for the treatment of pain and neurological conditions. The patent focuses on a compound for treating pain, depression, and schizophrenia, potentially improving withdrawal symptoms for opioid use disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.66%
Tags
-
Rhea-AI Summary
BioCorRx Inc. provided a business update for the year ended December 31, 2023, highlighting positive Phase I clinical trial results for BICX104, an implantable naltrexone pellet for opioid use disorder. The company also secured an $11 million grant for developing BICX104 for methamphetamine use disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
Rhea-AI Summary
BioCorRx Inc. announced that its subsidiary BioCorRx Pharmaceuticals Inc. has received an $11 million grant from NIDA to develop BICX104, a naltrexone implantable pellet for the treatment of methamphetamine use disorder. The grant aims to address the increasing prevalence of MUD and methamphetamine-related issues in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
-
News
Rhea-AI Summary
BioCorRx Inc. announced the appointment of Dr. Kate Beebe DeVarney, a renowned neuroscientist with 28 years of experience in the pharmaceutical industry, to its subsidiary BioCorRx Pharmaceuticals Inc.'s Board of Directors. Dr. DeVarney has a strong track record in developing and obtaining regulatory approval for treatments for people with substance use disorder. She will be instrumental in moving BICX104, an implantable naltrexone pellet for the treatment of opioid use disorder, through the regulatory pathway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
-
Rhea-AI Summary
BioCorRx Inc. (OTCQB: BICX) appoints Louis Lucido as Interim President, effective immediately through January 31, 2024, and as President on February 1, 2024. Brady Granier resigns as President and CEO of BioCorRx Pharmaceuticals, effective January 31, 2024. Mr. Granier will continue to serve as a Member of the Company’s Board of Directors. Louis Lucido brings extensive business acumen and experience in corporate finance and capital markets, having founded and helped run a multi-billion-dollar asset management firm. The Company plans for a Nasdaq listing, and Mr. Lucido aims to accelerate growth, increase market awareness, and drive value for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.85%
Tags
Rhea-AI Summary
BioCorRx Inc. (OTCQB: BICX) provided a business update for the three months ended September 30, 2023, highlighting positive safety and pharmacokinetic results for the Phase I clinical trial of BICX104, a treatment program for substance abuse. The company aims to address the opioid epidemic by offering enhanced relapse protection and managing expenses effectively. The quarterly report on Form 10-Q is available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.85%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.85%
Tags
Rhea-AI Summary
BioCorRx Inc. (OTCQB: BICX) has submitted a fast track application to the FDA for BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD). The fast track designation aims to expedite the development and review of new drugs intended to treat serious or life-threatening conditions, with the potential to fill unmet medical needs. The submission follows interim positive safety and pharmacokinetic results for the Phase I clinical trial, showing that BICX104 was generally well-tolerated and provided therapeutic levels of naltrexone for a mean of 84 days. The opioid overdose epidemic, causing an estimated 80,816 overdose deaths in 2021, is a significant public health crisis, and BioCorRx aims to make BICX104 available to patients and prescribers as soon as possible. The FDA typically responds to fast track designation requests within 60 days or less.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.82%
Tags
FAQ
What is the current stock price of BIOCORRX NEW (BICX)?
The current stock price of BIOCORRX NEW (BICX) is $0.525 as of January 23, 2025.
What is the market cap of BIOCORRX NEW (BICX)?
The market cap of BIOCORRX NEW (BICX) is approximately 6.7M.
What is BioCorRx Inc. (BICX) focused on?
BioCorRx is dedicated to improving the lives of individuals dealing with alcohol and opioid addiction by offering innovative treatment programs.
What sets BioCorRx's recovery program apart?
BioCorRx's program includes a proprietary naltrexone implant designed to substantially reduce cravings for drugs and alcohol, providing enhanced relapse protection during early treatment stages.
How does BioCorRx approach addiction treatment?
BioCorRx employs a high-quality, comprehensive, and cost-effective approach to recovery, built on experience and practice to deliver an improved quality of life for recovering addicts.
What recent achievements has BioCorRx celebrated?
BioCorRx has made significant strides in advancing the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for treating opioid use disorder.
What partnerships does BioCorRx have?
BioCorRx collaborates with a network of independently owned and operated treatment centers nationwide to provide access to its innovative recovery program.
How does BioCorRx impact the opioid public health crisis?
By offering solutions like BICX104, BioCorRx aims to significantly reduce opioid overdose deaths and make a meaningful impact on the drug epidemic.
What is BioCorRx's subsidiary BioCorRx Pharmaceuticals focused on?
BioCorRx Pharmaceuticals is dedicated to developing innovative treatments for substance use disorders, such as the long-duration naltrexone implantable pellet BICX104.
How does BioCorRx receive funding for its research and development efforts?
BioCorRx has been awarded substantial grants from institutions like the National Institute on Drug Abuse (NIDA) to support the development of groundbreaking treatments for substance use disorders.
What makes BioCorRx's approach to addiction treatment unique?
BioCorRx offers a comprehensive recovery program that combines Cognitive Behavioral Therapy, peer support, and medication prescribed by treating physicians to address substance use disorders effectively.
What is the focus of BioCorRx's subsidiary BioCorRx Pharmaceuticals?
BioCorRx Pharmaceuticals specializes in developing cutting-edge pharmaceutical solutions, including the implantable naltrexone pellet BICX104, designed to treat alcohol and opioid use disorders.
BIOCORRX INC NEW